Acumen Pharmaceuticals, Inc. Reclassifications of Temporary to Permanent Equity
Acumen Pharmaceuticals, Inc. (ABOS) reported Reclassifications of Temporary to Permanent Equity of $174.50 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-15.
Discontinued › Shareholders' Equity
us-gaap:ReclassificationsOfTemporaryToPermanentEquity · last filed 2021-11-15
- Acumen Pharmaceuticals, Inc. reclassifications of temporary to permanent equity for the quarter ending 2021-09-30 was $174.50M.
| Period end | Reclassifications of Temporary to Permanent Equity 3 month | Reclassifications of Temporary to Permanent Equity 9 month |
|---|---|---|
| 2021-09-30 | $174.50M 10-Q · filed 2021-11-15 | $174.50M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |